Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax
NCT ID: NCT01127880
Last Updated: 2010-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
50 participants
INTERVENTIONAL
2005-07-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Occult Pneumothorax in Patients With Blunt or Penetrating Trauma
NCT04188938
Negative Pleural Suction for Tube Thoracostomy in Patients With Chest Trauma
NCT01864577
Pleural Suction Additional to Thoracostomy Tube for Traumatic Hemothorax
NCT04525365
Pleural Abrasion Plus Minocycline Versus Apical Pleurectomy for Primary Spontaneous Pneumothorax
NCT00270751
Absorbable Mesh Pleurodesis in Thoracoscopic Treatment of Spontaneous Pneumothorax
NCT01848860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ancef 1 gm or Clindamycin 300 mg
Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists
Ancef or Clindamycin
1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
Placebo
Group B will receive .9% Normal Saline as a placebo.
Placebo
.9% Normal Saline as a placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ancef or Clindamycin
1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
Placebo
.9% Normal Saline as a placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Admission to Trauma, General Surgery, and/or Surgical Critical Care services.
3. Traumatic pneumothorax, hemothorax or hemopneumothorax
Exclusion Criteria
2. Open fracture
3. Immunocompromised
4. Require antibiotics for treatment of other injuries
5. Chest tube placement greater than 72hrs after admission
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Luke's Hospital, Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
St. Luke's Hospital and Health Network
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nathaniel McQuay, MD
Role: PRINCIPAL_INVESTIGATOR
St. Luke's Hospital and Health Network
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SLHN 2005-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.